
Beyond 200 mg/mL: The Science and Scaling of High-Dose Biologics
Episode 39
Pushing biologics beyond 200 mg/mL isn’t just a formulation challenge - it’s a delivery, manufacturing, and regulatory challenge too. Aggregation, precipitation, and sky-high viscosity make scaling these therapies a gauntlet for drug developers. In this episode of Life Science Solutions, host Chris Adkins continues the conversation on hyper-concentrated biologics with Ryan Doxey, VP of Tech Ops & CMC at Kymanox, and Nick Letourneau, PhD, Associate Director of Product Development & Commercialization. Together, they unpack how dehydrated protein microparticles suspended in hydrophobic carriers (like MCT oils or ethyl oleate) can dissolve instantly upon injection, and why this breakthrough could dramatically ease the patient experience. The conversation dives deep into what this means for manufacturing, device compatibility, and regulatory pathways, revealing how the future of injectables depends on solving problems once thought unsolvable.
Publisher
Life Science Solutions
Link
share.transistor.fm/s/18ad3912
Published
October 20, 2025
Duration
31 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
Kymanox
Life Science Solutions
@lifesciencesolutions
#scaling #high #dosebiologics #lifesciences
